Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / AGNPF - Algernon Pharmaceuticals releases details of Phase 2b chronic cough study of Ifenprodil

AGNPF - Algernon Pharmaceuticals releases details of Phase 2b chronic cough study of Ifenprodil

Algernon Pharmaceuticals Inc - Class A

--News Direct--

Algernon Pharmaceuticals CEO Christopher Moreau shared news that the company has announced it is planning a 180 patient, 3-month, Phase 2b clinical study of Ifenprodil for chronic cough. The study is set to begin in Q3 of 2023 and follows positive feedback from the US FDA at its pre-Investigational new drug meeting.

Contact Details

Proactive Canada

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/algernon-pharmaceuticals-releases-details-of-phase-2b-chronic-cough-study-of-ifenprodil-669427862

Stock Information
Company Name: Algernon Pharmaceuticals Inc - Class A
Stock Symbol: AGNPF
Market: OTC
Website: algernonpharmaceuticals.com
Menu
AGNPF AGNPF Quote AGNPF Short AGNPF News AGNPF Articles AGNPF Message Board
Get AGNPF Alerts

News, Short Squeeze, Breakout and More Instantly...